Published in FASEB J on April 10, 2002
A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal (2012) 2.03
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci (2010) 1.33
Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS (2011) 1.33
Detecting hidden sequence propensity for amyloid fibril formation. Protein Sci (2004) 1.25
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
Microglia function in Alzheimer's disease. Front Pharmacol (2012) 1.17
Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol (2007) 1.16
The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers Res Ther (2010) 1.09
Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm (Vienna) (2011) 0.99
Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets (2009) 0.98
Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol (2008) 0.98
Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des (2008) 0.97
The role of inflammasome in Alzheimer's disease. Ageing Res Rev (2014) 0.95
Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacol Sin (2011) 0.93
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev (2011) 0.91
Chaperoning G protein-coupled receptors: from cell biology to therapeutics. Endocr Rev (2014) 0.91
Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs. PLoS One (2011) 0.89
Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC Neurosci (2008) 0.86
Use of a small peptide fragment as an inhibitor of insulin fibrillation process: a study by high and low resolution spectroscopy. PLoS One (2013) 0.85
Peptides for therapy and diagnosis of Alzheimer's disease. Curr Pharm Des (2012) 0.85
Computational selection of inhibitors of Abeta aggregation and neuronal toxicity. Bioorg Med Chem (2009) 0.85
Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens. Pharmacol Res (2013) 0.81
Protein folding pathology in domestic animals. J Zhejiang Univ Sci (2004) 0.81
Escorts take the lead molecular chaperones as therapeutic targets. Prog Mol Biol Transl Sci (2010) 0.79
A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies. Mini Rev Med Chem (2012) 0.79
Assay strategies for identification of therapeutic leads that target protein trafficking. Trends Pharmacol Sci (2015) 0.78
Computational and experimental studies on β-sheet breakers targeting Aβ1-40 fibrils. J Biol Chem (2014) 0.78
The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. Clin Dev Immunol (2013) 0.77
Reversal of temperature-induced conformational changes in the amyloid-beta peptide, Abeta40, by the beta-sheet breaker peptides 16-23 and 17-24. Br J Pharmacol (2009) 0.77
Current experimental therapy for Alzheimer's disease. Curr Neuropharmacol (2007) 0.76
A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor. Assay Drug Dev Technol (2014) 0.76
An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Mol Med (2017) 0.75
In vitro generation of infectious scrapie prions. Cell (2005) 6.86
Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci (2006) 4.25
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med (2003) 3.57
Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem (2006) 2.98
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Prion strain mutation determined by prion protein conformational compatibility and primary structure. Science (2010) 2.71
Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol (2002) 2.67
Detection of prions in blood. Nat Med (2005) 2.66
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest (2004) 2.52
Brain-immune communication pathways. Brain Behav Immun (2007) 2.50
Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J (2003) 2.34
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Cell-free propagation of prion strains. EMBO J (2008) 2.20
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest (2007) 2.19
Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun (2005) 2.18
Strategies to advance translational research into brain barriers. Lancet Neurol (2008) 2.16
Presymptomatic detection of prions in blood. Science (2006) 2.14
Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell (2008) 2.09
Protein misfolding cyclic amplification for diagnosis and prion propagation studies. Methods Enzymol (2006) 2.04
Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem (2002) 2.02
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A (2004) 2.00
Effects of leptin on memory processing. Peptides (2005) 1.97
Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc Natl Acad Sci U S A (2004) 1.97
Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology (2008) 1.94
Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci (2002) 1.94
Accelerated high fidelity prion amplification within and across prion species barriers. PLoS Pathog (2008) 1.89
Isolation and characterization of a proteinase K-sensitive PrPSc fraction. Biochemistry (2006) 1.86
Detection of infectious prions in urine. FEBS Lett (2008) 1.85
De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog (2009) 1.83
Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. Am J Physiol Regul Integr Comp Physiol (2003) 1.82
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A (2006) 1.81
Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med (2014) 1.74
The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity. J Neurosci (2005) 1.74
The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem (2003) 1.67
Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol (2008) 1.65
Production of cattle lacking prion protein. Nat Biotechnol (2006) 1.63
Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. Proc Natl Acad Sci U S A (2008) 1.60
Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun (2003) 1.60
Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci (2003) 1.56
The capsaicin receptor TRPV1 is a crucial mediator of the noxious effects of mustard oil. Curr Biol (2011) 1.56
The effects of animal-assisted therapy on loneliness in an elderly population in long-term care facilities. J Gerontol A Biol Sci Med Sci (2002) 1.51
Stressing out the ER: a role of the unfolded protein response in prion-related disorders. Curr Mol Med (2006) 1.49
Cyclic amplification of protein misfolding and aggregation. Methods Mol Biol (2005) 1.48
Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology (2008) 1.47
Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab (2013) 1.45
Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation (2005) 1.45
Estimating prion concentration in fluids and tissues by quantitative PMCA. Nat Methods (2010) 1.40
Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem (2004) 1.40
The prion strain phenomenon: molecular basis and unprecedented features. Biochim Biophys Acta (2006) 1.39
HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res (2005) 1.39
Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology (2002) 1.36
Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides (2007) 1.35
Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem (2003) 1.34
Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci (2010) 1.33
Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun (2009) 1.32
Prion protein glycosylation is not required for strain-specific neurotropism. J Virol (2009) 1.31
In vivo generation of neurotoxic prion protein: role for hsp70 in accumulation of misfolded isoforms. PLoS Genet (2009) 1.29
A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab (Lond) (2005) 1.29
Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol Cell Biol (2012) 1.28
Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes (2006) 1.27
Amyloid formation modulates the biological activity of a bacterial protein. J Biol Chem (2005) 1.27
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem (2005) 1.26
Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol (2011) 1.25
AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One (2009) 1.23
Animal-assisted therapy and loneliness in nursing homes: use of robotic versus living dogs. J Am Med Dir Assoc (2008) 1.23
Cyclic amplification of protein misfolding: application to prion-related disorders and beyond. Trends Neurosci (2002) 1.21
Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. J Biol Chem (2002) 1.20
Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor. Proc Natl Acad Sci U S A (2007) 1.18
Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol Cell Biol (2012) 1.18
Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab (2009) 1.17
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide. J Neuroinflammation (2011) 1.16
Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim Biophys Acta (2008) 1.15
Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: multiplex quantification with path analysis. Brain Behav Immun (2011) 1.15
Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol Ther (2008) 1.14
Perturbation of endoplasmic reticulum homeostasis facilitates prion replication. J Biol Chem (2007) 1.13
Generation of a new form of human PrP(Sc) in vitro by interspecies transmission from cervid prions. J Biol Chem (2011) 1.12
A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol (2006) 1.12
Prion protein misfolding affects calcium homeostasis and sensitizes cells to endoplasmic reticulum stress. PLoS One (2010) 1.11
Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology (2011) 1.11
Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation. EMBO Mol Med (2011) 1.11
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer (2010) 1.10
Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog (2013) 1.10
Protein misfolding cyclic amplification of infectious prions. Nat Protoc (2012) 1.10
Is loss of function of the prion protein the cause of prion disorders? Trends Mol Med (2003) 1.10
Lipopolysaccharide impairs amyloid β efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation (2012) 1.09
Production and release of yessotoxins by the dinoflagellates Protoceratium reticulatum and Lingulodinium polyedrum in culture. Toxicon (2004) 1.09
Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A (2011) 1.09
GSK3 and Alzheimer's Disease: Facts and Fiction…. Front Mol Neurosci (2011) 1.09